A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Cystic Fibrosis
Sponsor: |
PTC Therapeutics |
Enrolling: |
Male and Female Patients |
Study Length: |
1 Years |
IRB Number: |
AAAO2702 |
U.S. Govt. ID: |
NCT02139306 |
Contact: |
Eva Aquino: 212-305-4675 / ema2180@columbia.edu |
The purpose of this study is to find out whether the study drug altaluren can help lung function and can reduce the symptoms associated with cystic fibrosis (CF), and decrease the number of hospitalizations and the use of antibiotics for CF-related lung infections. The study will also investigate whether the drug can help improve overall patient quality of life and is safe for children and adults to take as long-term treatment.
This study is closed
Investigator
Emily DiMango, MD
Do you have any known hypersensitivity to any of the ingredients of altaluren? |
Yes |
No |